Brokerages forecast that Accuray Incorporated (NASDAQ:ARAY) will announce earnings of ($0.01) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Accuray’s earnings. Accuray also posted earnings per share of ($0.01) in the same quarter last year. The company is expected to announce its next quarterly earnings report on Thursday, August 12th.
On average, analysts expect that Accuray will report full year earnings of $0.03 per share for the current fiscal year, with EPS estimates ranging from $0.01 to $0.04. For the next year, analysts expect that the firm will report earnings of $0.08 per share, with EPS estimates ranging from $0.02 to $0.11. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Accuray.
Separately, Zacks Investment Research cut Accuray from a “hold” rating to a “sell” rating and set a $5.00 target price for the company. in a research note on Thursday, April 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $7.25.
Several hedge funds have recently bought and sold shares of ARAY. First Trust Advisors LP acquired a new position in shares of Accuray during the first quarter worth about $298,000. Parallel Advisors LLC boosted its position in shares of Accuray by 20.1% during the fourth quarter. Parallel Advisors LLC now owns 174,701 shares of the medical equipment provider’s stock worth $729,000 after buying an additional 29,220 shares during the period. Bailard Inc. acquired a new position in shares of Accuray during the fourth quarter worth about $181,000. GSA Capital Partners LLP boosted its position in shares of Accuray by 8.1% during the fourth quarter. GSA Capital Partners LLP now owns 128,976 shares of the medical equipment provider’s stock worth $538,000 after buying an additional 9,683 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Accuray during the fourth quarter worth about $157,000. 73.86% of the stock is owned by institutional investors.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Story: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.